Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telmisartan Pilot Study on Treatment Resistant Schizophrenia
NCT03868839Phase 2Terminated
- Start
- Feb 2019
- Primary completion
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of telmisartan in schizophrenia and schizoaffective disorder. Primary endpoints: Changes in Blood Levels of Tumor Necrosis Factor Alpha at 4 weeks, Changes in Blood Levels of Glutathione at 4 weeks and 2 more. Started Feb 2019; status: terminated.
02
Drugs
telmisartan
03
Conditions
schizophreniaschizoaffective disorder
Beyond the preview
Go deeper on NCT03868839.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03868839.